AstraZeneca withdraws global Covid vaccine, cites commercial reasons: report.

Experts expect that all “monovalent” vaccines targeting the original Covid strain will be withdrawn. AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine following reports of rare side effects.

The vaccine, known as Covishield, was produced by the Serum Institute of India and is no longer being produced or used. This withdrawal will also take place in other countries that have been using the vaccine.

AstraZeneca is facing legal action in the UK over claims that the vaccine caused deaths and injuries. The company admitted that the vaccine can cause rare side effects, such as TTS (Thrombosis with Thrombocytopenia Syndrome), which has been linked to at least 81 deaths in the UK.

However, AstraZeneca denies that the decision to withdraw Covishield is linked to the court case. The pharmaceutical company has stated that its efforts have been recognized by governments around the world and are regarded as a critical component in ending the global pandemic.

As multiple updated vaccines for variant Covid-19 strains have been developed, there is a surplus of available vaccines. Experts anticipate that the “monovalent” vaccines targeting the original Covid strain will be replaced with updated vaccines that address a wider range of strains.